-
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
September 19, 2023 -
CytoSorb with Ex Vivo Organ Perfusion: Transforming the Future of Solid Organ Transplantation
September 11, 2023 -
CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
September 1, 2023
-
CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
July 26, 2023 -
CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
July 19, 2023 -
CytoSorbents And Humedics Announce Theranostic Collaboration in the Field of Liver Disease
July 11, 2023 -
CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
July 7, 2023
-
CytoSorbents Announces Independent Data Safety and Monitoring Board Recommends Completion of the Pivotal STAR-T Trial Without Modifications Following Second Scheduled Safety Review
June 15, 2023 -
CytoSorbents This Week to Host its Virtual Annual Stockholders Meeting and to Present at the Jefferies Healthcare Conference
June 5, 2023
-
CytoSorbents Reports First Quarter 2023 Results
May 2, 2023
-
Landmark Publication Underscores Robust Ability of CytoSorb to Reduce Cytokine Storm during Systemic Hyperinflammation
March 29, 2023 -
CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)
March 22, 2023 -
CytoSorbents Comments on Bank Exposure and Diversified Cash Position
March 14, 2023 -
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
March 9, 2023 -
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
March 7, 2023
-
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference
February 27, 2023 -
CytoSorbents to Report Fiscal 2022 Operating and Financial Results
February 24, 2023
-
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
January 31, 2023 -
CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial
January 23, 2023 -
CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs
January 17, 2023
-
CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled
November 14, 2022 -
CytoSorbents Reports Third Quarter 2022 Financial and Operational Results
November 3, 2022 -
‘Enhanced Lung Rest’ with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals
November 2, 2022
-
National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma
October 31, 2022 -
CytoSorbents to Report Third Quarter 2022 Operating and Financial Results
October 27, 2022 -
CytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
October 12, 2022 -
CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch
October 7, 2022 -
CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma
October 6, 2022 -
CytoSorbents to Present at the Dawson James Securities 2022 Small Cap Growth Conference
October 4, 2022
-
CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey
September 27, 2022 -
The U.S. Department of Defense Awards CytoSorbents an Approximately $2.0M Contract to Support HemoDefend-BGA™ Development for Life-saving Universal Plasma
September 9, 2022 -
CytoSorbents to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 7, 2022
-
Turkish Ministry of Health Grants National Reimbursement to CytoSorb®
August 23, 2022 -
Israeli Ministry of Health Approves National Coverage for CytoSorb®
August 17, 2022 -
CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms
August 2, 2022 -
CytoSorbents Reports Second Quarter 2022 Financial and Operational Results
-
CytoSorbents to Report Second Quarter 2022 Operating and Financial Results
July 25, 2022 -
The 2022 CytoSorb World Users’ Meeting Highlights the Broad Market Potential of CytoSorb as an Interdisciplinary Therapeutic Approach
July 8, 2022 -
Leading Critical Care and Cardiac Surgery Specialists from 40 Countries Meet to Discuss CytoSorb and the New Dimension in Blood Purification
July 1, 2022
-
First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery
April 29, 2022 -
CytoSorbents Highlights the Strategy of “Enhanced Lung Rest” Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress
April 28, 2022 -
CytoSorbents to Report First Quarter 2022 Operating and Financial Results
April 19, 2022 -
CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World
April 14, 2022 -
CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program
April 7, 2022 -
CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors
April 5, 2022
-
CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results
February 8, 2022 -
CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences
February 3, 2022 -
First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock
February 1, 2022
-
New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents’ Antithrombotic Drug Removal Technology
January 24, 2022 -
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
January 18, 2022
-
CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular
December 21, 2021 -
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
December 20, 2021
-
CytoSorbents Comments on REMOVE Study Presentation
October 20, 2021 -
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery
October 14, 2021 -
CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery
October 12, 2021 -
CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance
-
CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference
October 7, 2021
-
CytoSorbents to Host International Webinar on the Worldwide Experience Using CytoSorb® in Critically Ill Patients with COVID-19
September 14, 2021 -
CytoSorbents Commemorates World Sepsis Day and Sepsis Awareness Month with Key Sepsis-Related Events, Sponsorships and Studies
September 13, 2021 -
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery
September 10, 2021 -
CytoSorbents Announces Webinar Discussing Topline Results from the U.S. CTC Registry using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
September 8, 2021 -
Topline Results from CytoSorbents’ U.S. CTC Multicenter Registry Demonstrate High Survival using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
September 1, 2021
-
CytoSorbents and Aferetica Announce the Commercial Launch in Italy of the PerSorb™ Adsorber and PerLife™ Organ Perfusion System, respectively, at the European Society of Organ Transplantation Congress
August 30, 2021 -
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents’ DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
August 12, 2021 -
CytoSorbents Reports Second Quarter 2021 Financial and Operational Results
August 3, 2021
-
CytoSorbents Completes its Mission 100,000 International Fundraising Campaign to Fight the Spread of COVID-19 for Global Humanitarian Organization, CARE
July 30, 2021 -
CytoSorbents to Report Second Quarter 2021 Operating and Financial Results
July 19, 2021 -
CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
July 6, 2021
-
CytoSorbents to Present at the Jefferies Virtual Healthcare Conference
May 27, 2021 -
CytoSorb® Registered and Commercially Available in Singapore
May 25, 2021 -
CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit
May 19, 2021 -
CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury
May 11, 2021 -
CytoSorbents Reports First Quarter 2021 Financial and Operational Results
May 4, 2021
-
CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey
March 29, 2021 -
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardiothoracic Surgery
March 16, 2021 -
CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference
March 12, 2021 -
CytoSorbents Announces 2020 Financial and Operational Results
March 9, 2021 -
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
March 2, 2021 -
CytoSorbents to Report Fiscal 2020 Operating and Financial Results
March 1, 2021
-
CytoSorbents to Present at the Cowen 41st Annual Health Care Conference
February 24, 2021 -
CytoSorbents 2021: Leadership and Growth in the “New Normal”
February 18, 2021 -
CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 16, 2021 -
National Institute for Health and Care Excellence (NICE) Issues Medtech Innovation Briefing on CytoSorb for Reducing Risk of Bleeding During Cardiac Surgery
February 4, 2021
-
CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President – Global Regulatory Affairs
January 21, 2021 -
CytoSorbents Announces Approval of CytoSorb® in Korea in Collaboration with Partner Fresenius Medical Care
January 19, 2021 -
Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
January 12, 2021 -
CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue
-
CytoSorbents Appoints James Komsa as Vice President – U.S. Sales and Marketing
January 11, 2021 -
Health Canada Authorizes CytoSorb for Use in Hospitalized COVID-19 Patients
January 4, 2021
-
CytoSorbents Promotes Dr. Christian Steiner to Executive Vice President of Sales and Marketing
December 17, 2020 -
CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank
December 10, 2020 -
Early CytoSorb Initiation Improves Hemodynamic Stabilization and Survival in New Septic Shock Study
December 9, 2020 -
CytoSorbents Launches International Campaign to Raise $100,000 for the Global Humanitarian Organization, CARE
December 2, 2020
-
CytoSorbents Highlights Largest Published Case Series To Date Using CytoSorb in Critically Ill COVID-19 Patients
November 25, 2020 -
CytoSorbents to Present at the Piper Sandler 32nd Annual Healthcare Conference
November 23, 2020 -
CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference
November 12, 2020 -
CytoSorbents Reports Record Third Quarter 2020 Financial Results
November 4, 2020
-
CytoSorbents to Report Q3 2020 Operating and Financial Results
October 21, 2020 -
CytoSorbents and Aferetica Announce European Union Approval of the PerLife™ System and ECOS-300CY™ PerSorb™ Cartridge for Combined Perfusion and Purification of Solid Organs Dedicated to Transplant
October 14, 2020 -
The U.S. Department of Defense Awards $1.1 Million to CytoSorbents to Optimize Development of HemoDefend-BGA™ for Life-saving Universal Plasma
October 9, 2020
-
CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other Conditions
September 21, 2020 -
CytoSorbents Highlights CytoSorb Use in Sepsis Patients During Sepsis Awareness Month and World Sepsis Day 2020
September 11, 2020 -
CytoSorbents Announces the “CytoSorb Therapy in COVID-19 ICU Patients” (CTC) Registry Is Actively Enrolling
September 8, 2020
-
Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19
August 24, 2020 -
CytoSorbents Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under FDA Emergency Use Authorization for COVID-19
August 17, 2020 -
CytoSorbents Reports Record Second Quarter 2020 Financial Results
August 4, 2020 -
CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date
August 3, 2020
-
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development
July 31, 2020 -
CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data
July 28, 2020 -
CytoSorbents to Report Q2 2020 Operating and Financial Results
-
CytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common Stock
July 22, 2020 -
CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update
July 20, 2020 -
CytoSorbents Corporation Announces Proposed $40 Million Public Offering of Common Stock
-
C O R R E C T I O N — CytoSorbents Corporation
July 8, 2020
-
CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding
June 29, 2020 -
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise
June 24, 2020 -
CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials
June 9, 2020
-
CytoSorbents Announces Virtual Annual Meeting
May 27, 2020 -
CytoSorb® is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
May 12, 2020 -
CytoSorbents Reports First Quarter 2020 Financial and Operational Results
May 5, 2020 -
CytoSorbents Promotes Vincent J. Capponi to President
May 4, 2020
-
CytoSorbents Receives $1.1 Million in Non-Dilutive Funding from the New Jersey Business Tax Certificate Transfer Program
April 29, 2020 -
CytoSorbents to Report Q1 2020 Operating and Financial Results
April 28, 2020 -
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
April 27, 2020 -
Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb for Removal of Ticagrelor During Cardiopulmonary Bypass in Emergent and Urgent Cardiothoracic Surgery
April 20, 2020 -
New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on ECMO
April 15, 2020 -
U.S. FDA Grants CytoSorb® Emergency Use Authorization for Use in Patients with COVID-19 Infection
April 13, 2020 -
CytoSorbents CEO to Discuss COVID-19 Pandemic and its CytoSorb® Treatment of Cytokine Storm in Cowen COVID-19 Series Conference Call Today
April 3, 2020
-
CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
March 31, 2020 -
CytoSorb® Used to Treat More than 70 Critically-Ill COVID-19 Patients and Specifically Added to Coronavirus Treatment Guidelines in Italy and Panama
March 25, 2020 -
CytoSorbents Provides Update on CytoSorb and COVID-19 Coronavirus Activities
March 12, 2020 -
CytoSorbents Announces 2019 Financial and Operational Results
March 5, 2020 -
CytoSorbents Highlights Recent Publication Using CytoSorb during Cardiac Surgery for Infective Endocarditits
March 2, 2020
-
CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection
February 19, 2020 -
CytoSorb Used Successfully to Help Treat Grade 4 Cytokine Release Syndrome Following CAR T-cell Immunotherapy in First Published Case Report
February 5, 2020
-
CytoSorb® is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
January 29, 2020 -
CytoSorb, the Wuhan Coronavirus, and Cytokine Storm
January 28, 2020 -
CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin
January 22, 2020 -
CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter
January 14, 2020 -
CytoSorbents to Present at Biotech Showcase™ 2020
January 7, 2020
-
CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study
November 25, 2019 -
CytoSorbents to Present at the Three Part Advisors 2019 Southwest IDEAS Investor Conference
November 19, 2019 -
Dr. Eric Mortensen to Leave CytoSorbents At Year End
November 6, 2019 -
CytoSorbents Reports Third Quarter 2019 Financial Results
November 5, 2019 -
CytoSorbents Announces Additions to its International Clinical Team
November 4, 2019 -
CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom
November 1, 2019
-
CytoSorbents to Report Q3 2019 Operating and Financial Results
October 30, 2019 -
CytoSorbents Awarded Approximately $3.0 Million by the U.S. Air Force to Advance Development of the K+ontrol System to Treat Severe Hyperkalemia
October 22, 2019 -
CytoSorbents to Present at The MicroCap Rodeo Investor Conference
October 10, 2019 -
CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery
October 4, 2019 -
CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery
October 2, 2019
-
CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock
September 25, 2019 -
First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence
September 16, 2019 -
World Sepsis Day 2019: CytoSorbents Highlights Its Support of Multiple Organizations In the Fight Against Sepsis
September 13, 2019 -
CytoSorbents to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 9, 2019
-
CytoSorbents Highlights Recent Published Studies on CytoSorb
August 28, 2019 -
CytoSorbents Receives Renewal of CytoSorb® CE Mark Through May 2024 and Annual ISO 13485:2016 Certification Through September 2022
August 15, 2019 -
CytoSorbents Expands CytoSorb Distribution in Latin America to Brazil, Colombia, and Costa Rica
August 13, 2019 -
CytoSorbents Reports Record Second Quarter 2019 Financial Results
August 6, 2019 -
CytoSorbents Announces Amendment to Loan Agreement with Bridge Bank, Receives an Additional $5 Million Cash from New Term Loan
August 5, 2019
-
CytoSorbents to Report Fiscal 2018 Operating and Financial Results
February 28, 2019 -
CytoSorbents to Participate at the 8th Annual SVB Leerink Global Healthcare Conference
February 25, 2019 -
CytoSorbents to Present at the 21st Annual BIO CEO & Investor Conference
February 5, 2019 -
CytoSorbents Announces the Data Safety Monitoring Board Recommends Continuation of REMOVE Endocarditis Trial
February 4, 2019
-
CytoSorbents to Present at the 30th Annual Piper Jaffray Healthcare Conference
November 26, 2018 -
CytoSorbents Recognized Again as One of the Fastest Growing Companies in North America on Deloitte’s 2018 Technology Fast 500™
November 19, 2018 -
CytoSorbents to Present at the Stifel, Jefferies, and Canaccord Investor Conferences This Week
November 12, 2018 -
CytoSorbents Reports Third Quarter 2018 Financial Results
November 6, 2018
-
CytoSorb® Assigned Dedicated Procedure Code in Switzerland
September 20, 2018 -
World Sepsis Day 2018: CytoSorbents Sponsors the Sepsis Heroes Gala and the Roger Bone Award for Excellence in Sepsis Research
September 13, 2018 -
CytoSorbents REFRESH 2-AKI Protocol Amendment Approved by FDA
September 4, 2018
-
CytoSorbents to Present at the B. Riley FBR Healthcare Conference and the H.C. Wainwright 20th Annual Global Investment Conference
August 28, 2018 -
CytoSorbents Awarded up to $3M in SBIR Phase IIB Bridge Funding by NIH/NHLBI to Accelerate U.S. Approval and Commercialization of the HemoDefend™ Blood Transfusion Filter
August 21, 2018 -
CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018
August 2, 2018
-
CytoSorbents Expands Distribution of CytoSorb® to a Total of 53 Countries Worldwide
July 31, 2018 -
CytoSorbents to Report Q2 2018 Operating and Financial Results
July 26, 2018 -
Aferetica and CytoSorbents Debut the PerLife™ System for Organ Preservation and Rehabilitation at the 27th International Congress of the Transplantation Society
July 9, 2018
-
CytoSorbents to Present at the 19th Annual B. Riley FBR Investor Conference
May 21, 2018 -
CytoSorb® Adds Bilirubin and Myoglobin Reduction to European Union Approved Indications for Use
May 14, 2018 -
CytoSorbents Reports Strong First Quarter 2018 Financial Results
May 8, 2018 -
CytoSorbents to Report Q1 2018 Operating and Financial Results
May 2, 2018
-
CytoSorbents Enrolls First Patient into Pivotal U.S. REFRESH 2-AKI Trial Using CytoSorb® During Complex Cardiac Surgery
April 24, 2018 -
CytoSorbents to Meet With European Investors at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo and in Meetings in Frankfurt, Geneva and Zurich
April 9, 2018 -
CytoSorbents Refinances Existing Debt with New $15 Million Debt Facility with Bridge Bank
April 4, 2018
-
CytoSorbents Reports on the Successful 5th International CytoSorb Users Meeting and 38th ISICEM Critical Care Conference
March 28, 2018 -
CytoSorbents to Present at the 38th Annual Cowen Healthcare Conference
March 12, 2018 -
CytoSorbents Achieves Record Revenue and Product Sales Growth in 2017
March 8, 2018 -
CytoSorbents to Report Fiscal 2017 Operating and Financial Results
March 1, 2018
-
CytoSorbents to Participate at the BTIG Healthcare Conference
February 26, 2018 -
CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia
February 15, 2018 -
CytoSorbents to Present at the 20th Annual BIO CEO & Investor Conference
February 6, 2018 -
New Study Demonstrates Improved Hemodynamic Stability After Heart Transplant Surgery using Intraoperative CytoSorb® Blood Purification
February 1, 2018
-
CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application
December 21, 2017 -
CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
December 19, 2017 -
German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial
December 11, 2017
-
CytoSorbents to Present at the LD Micro Main Event Investor Conference 2017
November 29, 2017 -
CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017
November 9, 2017 -
CytoSorbents Recognized on Deloitte’s 2017 Technology Fast 500™ as One of the Fastest Growing Companies in North America
-
CytoSorbents to Report Q3 2017 Operating and Financial Results
November 2, 2017 -
CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia
November 1, 2017
-
CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress
September 26, 2017 -
Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®
September 25, 2017 -
World Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony
September 14, 2017 -
Aferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation
September 11, 2017 -
CytoSorbents to Present at the 2017 Rodman & Renshaw Annual Global Investment Conference
September 6, 2017 -
CytoSorbents Highlights Important Research Advances in Traumatic Brain Injury, Hemorrhagic Shock, and Severe Hyperkalemia at the Military Health System Research Symposium
September 5, 2017
-
CytoSorbents Expands Distribution and Sales of CytoSorb® to treat Deadly Inflammation in Panama with DRGR
July 17, 2017 -
CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma
July 13, 2017 -
CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank
July 5, 2017
-
Dr. Eric R. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer
May 30, 2017 -
CytoSorbents Selected to Present at Special Operations SOMSA 2017 Conference and 18th Annual B. Riley & Co. Investor Conference
May 24, 2017 -
Aferetica and CytoSorbents Extend Exclusive “Life-saving” Partnership through 2021
May 22, 2017 -
CytoSorbents Reports First Quarter 2017 Financial Results
May 8, 2017 -
CytoSorbents Announces Positive REFRESH I Trial Results
May 5, 2017 -
CytoSorbents to Report Q1 2017 Operating and Financial Results
May 2, 2017
-
CytoSorbents Announces Pricing of Follow-On Offering
March 31, 2017 -
CytoSorbents Announces Proposed Offering of Common Stock
March 30, 2017 -
CytoSorbents Strengthens Intellectual Property Portfolio with New Patents Issued in the U.S., China, Japan, Russia, and Australia
March 28, 2017 -
CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference
March 27, 2017 -
Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board
March 22, 2017 -
CytoSorb® Treatment of HLH – The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy
March 20, 2017 -
CytoSorbents Announces CytoSorb® Partnership with Dr. Reddy’s Laboratories
March 16, 2017 -
CytoSorbents Highlights Activities at the 22nd International Conference on Advances in Critical Care Nephrology
March 7, 2017 -
CytoSorbents to Present at the Maxim Group – Haitong Securities Inaugural Healthcare Investor and Partnering Conference
March 6, 2017 -
CytoSorbents Reports Record Quarterly and Full-Year 2016 Revenue
March 3, 2017 -
CytoSorbents to Present at 37th Annual Cowen and Company Healthcare Conference
March 2, 2017
-
CytoSorbents to Report Fiscal 2016 Operating and Financial Results
February 24, 2017 -
CytoSorbents to Present at the 19th Annual BIO CEO & Investor Conference
February 7, 2017
-
CytoSorbents Launches VetResQ™ for U.S. Veterinary Market
January 20, 2017 -
CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results
January 10, 2017 -
Fresenius Medical Care and CytoSorbents Expand Original Partnership and Add New Co-Marketing Agreement for Worldwide CytoSorb® Markets
January 9, 2017 -
CytoSorbents To Provide Corporate Update at Biotech Showcase 2017
January 3, 2017
-
CytoSorbents Announces First Sales of New CytoSorb® CPB Procedure Pack for Cardiac Surgery
December 20, 2016 -
CytoSorbents Receives $318,551 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
December 12, 2016 -
CytoSorb® Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany Expected to Catalyze Major Increases in Adoption and Sales of CytoSorb® in Germany
December 7, 2016 -
CytoSorbents to Present at the LD Micro Main Event Investor Conference
December 2, 2016 -
CytoSorb® Selected for NICE MedTech Innovation Briefing in the United Kingdom
December 1, 2016
-
First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb®
November 22, 2016 -
CytoSorbents Reports Highlights from the SepsEast 2016 Critical Care Congress
November 17, 2016 -
Adrian Thomas Joins CytoSorbents to Drive Western European Sales
November 15, 2016 -
CytoSorb® Q3 2016 Sales Reach Record $2.14M, Doubling From a Year Ago
November 7, 2016 -
CytoSorbents Expands Direct Sales of CytoSorb to Belgium and Luxembourg
November 3, 2016 -
CytoSorbents to Report Q3 2016 Operating and Financial Results
November 1, 2016
-
CytoSorbents Congratulates Kathleen Bloch as NJBIZ Public Company Chief Financial Officer of the Year
October 17, 2016 -
CytoSorbents to Present at the 2016 BIO Investor Forum
October 14, 2016 -
CytoSorbents and Foxx Medical Begin Saving Lives in Chile with CytoSorb®
October 11, 2016 -
CytoSorbents Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial
October 5, 2016 -
International Marketing of CytoSorb® Commences at European Association for Cardio-Thoracic Surgery Conference
October 3, 2016
-
New CytoSorbents Website Highlights Global Growth and Innovation
September 29, 2016 -
CytoSorbents Expands CytoSorb® into Iran with Partner Arsak
September 23, 2016 -
CytoSorbents Sponsors Sepsis Heroes Gala in Honor of World Sepsis Day
September 15, 2016 -
Terumo Cardiovascular Group and CytoSorbents Announce CytoSorb Cardiac Surgery Partnership
September 12, 2016 -
CytoSorbents Advances War On Sepsis with Development of CytoSorb-XL
September 8, 2016 -
CytoSorbents to Present at the 2016 Rodman & Renshaw Annual Global Investment Conference
September 7, 2016
-
CytoSorbents Achieves Fourth Consecutive Quarter of Record CytoSorb® Sales
August 9, 2016 -
CytoSorbents Awarded $650,000 in SBIR Grant Contracts to Continue Development of Novel Hemocompatible Potassium Binding Polymers
August 8, 2016 -
CytoSorbents to Report Q2 2016 Operating and Financial Results
August 2, 2016
-
Independent Data Safety Monitoring Board Recommends Continuation of CytoSorbents REFRESH I Trial
May 27, 2016 -
CytoSorb® Achieves Final Product Registration in Russia
May 18, 2016 -
CytoSorbents Continues Strong Growth in Q1 2016
May 9, 2016 -
CytoSorbents Establishes Swiss Subsidiary
May 6, 2016 -
CytoSorbents to Report Q1 2016 Operating and Financial Results
May 2, 2016
-
CytoSorbents Awarded $150,000 Phase I SBIR Contract for Fungal Mycotoxin Removal
March 25, 2016 -
CytoSorbents Reports on Successful 3rd International CytoSorb® Users Meeting
March 16, 2016 -
CytoSorbents to Host 3rd International CytoSorb® Users Meeting and ISICEM 2016 Symposium
March 14, 2016 -
CytoSorbents Reports Record Quarterly and Full-Year 2015 Revenue
March 9, 2016 -
CytoSorbents to Report Fiscal 2015 Operating and Financial Results
March 2, 2016
-
Data Presented on First CytoSorb® Investigator-Initiated Septic Shock Study
February 26, 2016 -
CytoSorbents to Exhibit at the 45th Society of Critical Care Medicine Congress
February 18, 2016 -
CytoSorbents Announces 26th Symposium for Intensive Medicine and Intensive Care Agenda in Bremen, Germany
February 16, 2016 -
CytoSorbents to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
February 4, 2016 -
CytoSorbents Receives $325,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
February 1, 2016
-
CytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference
January 28, 2016 -
CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs
January 21, 2016 -
CytoSorbents 2016 – Driving Toward the Inflection Point
January 11, 2016 -
CytoSorbents To Present at Biotech Showcase 2016
January 4, 2016
-
CytoSorbents Issues EAP Update
December 21, 2015 -
CytoSorbents Expands Distribution of CytoSorb® to Vietnam
December 15, 2015 -
CytoSorbents to Ring Opening Bell to Celebrate One Year NASDAQ Anniversary
December 9, 2015
-
CytoSorbents Accelerates Growth in Q3 2015
November 13, 2015 -
CytoSorbents To Meet With Investors at Brean Capital Life Sciences Summit and Stifel 2015 Healthcare Conference
November 9, 2015 -
CytoSorbents to Report Q3 2015 Operating and Financial Results
November 6, 2015
-
CytoSorbents Ready for Second International CytoSorb® Users Meeting, ESICM and EACTS Conferences
September 30, 2015 -
World Sepsis Day 2015: CytoSorbents Sponsors the SepsisUpdate 2015 Congress, Hugo Schottmuller Prize, and Sepsis Heroes Ceremony
September 14, 2015 -
CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference
September 2, 2015
-
CytoSorbents Reports Steady Growth in Q2 2015
August 13, 2015 -
Saudi Food and Drug Authority Approves CytoSorb®
August 10, 2015 -
CytoSorbents to Report Q2 2015 Operating and Financial Results
August 6, 2015
